Table 1.
Clinical characteristics at time of first allo-HSCT
| Patients | Total cohort | Day-100 landmark cohort | Day-100 landmark and DLI | ||
|---|---|---|---|---|---|
| no DLI | preDLI | relDLI | |||
| Number | 342 | 292 | 199 | 42 | 51 |
| Age [median (range)] | 57 (19-79) | 57 (19-78) | 57 (19-78) | 57 (32-75) | 56 (22-78) |
| AML type | |||||
| De novo | 235 (69%) | 205 (70%) | 135 (68%) | 34 (81%) | 36 (71%) |
| sAML/tAMLa | 107 (31%) | 87 (30%) | 64 (32%) | 8 (29%) | 15 (29%) |
| Status pre-HSCT | |||||
| Complete remission | 145 (42%) | 134 (46%) | 95 (48%) | 20 (48%) | 19 (37%) |
| CR1 | 122 | 111 | 79 | 17 | 15 |
| CR2 or higher | 23 | 23 | 16 | 3 | 4 |
| Active disease | 197 (58%) | 158 (54%) | 104 (52%) | 22 (52%) | 32 (63%) |
| PIF | 109 | 84 | 56 | 9 | 19 |
| REL1 | 40 | 33 | 20 | 6 | 7 |
| REL2 or higher | 2 | 2 | 1 | 1 | - |
| Progression | 5 | 3 | 3 | - | - |
| Untreatedb | 41 | 36 | 24 | 6 | 6 |
| Conditioning | |||||
| Myeloablative | 85 (21%) | 75 (26%) | 47 (24%) | 12 (29%) | 16 (31%) |
| BU/CY-based | 54 | 48 | 26 | 8 | 14 |
| TT/BU/FLU | 31 | 27 | 21 | 4 | 2 |
| Toxicity-reduced | 257 (79%) | 217 (74%) | 152 (76%) | 30 (71%) | 35 (69%) |
| FLU/BCNU/MEL | 181 | 153 | 102 | 24 | 27 |
| FLU/TT-based | 68 | 56 | 50 | 3 | 3 |
| Other FLU or TT | 8 | 8 | - | 3 | 5 |
| HLA donor-to-recipient | |||||
| Unrelated matched | 191 (56%) | 164 (56%) | 112 (56%) | 23 (55%) | 29 (57%) |
| Unrelated mismatched | 70 (20%) | 59 (20%) | 37 (19%) | 7 (17%) | 15 (29%) |
| Sibling matched | 72 (21%) | 62 (21%) | 44 (22%) | 11 (26%) | 7 (14%) |
| Sibling mismatched | 4 (1%) | 3 (1%) | 2 (1%) | 1 (2%) | - |
| Othersc | 5 (1.5%) | 4 (1.4%) | 4 (2%) | - | - |
aAbbreviations: sAML/tAML secondary or therapy-related AML, CR complete remission, PIF primary induction failure, REL relapse, BU busulfan, CY cyclophosphamide, FLU fludarabine, BCNU carmustine, MEL melphalan, TT thiotepa. bUp-front allo-HSCT predominantly in patients with sAML/tAML (32 of 41, total cohort; 29 of 36, day-100 landmark cohort; 12 of 12, DLI cohorts). cIdentical twins (2); haploidentical (2) or HLA-matched (1) child